Update: Daiichi Sankyo says Plexxikon R&D unit will close downJust over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the Share XUpdate: Daiichi Sankyo says Plexxikon R&D unit will close downhttps://pharmaphorum.com/news/daiichi-sankyo-says-plexxikon-rd-unit-will-close-down/
Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and moreAZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, Share XOncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and morehttps://pharmaphorum.com/views-and-analysis/oncology-round-up-az-and-daiichi-score-key-trial-win-with-breast-cancer-antibody-and-more/
CRUK tests drug combo for advanced pancreatic cancerCancer Research UK has announced it will study Plexxikon’s dual kinase inhibitor PLX7486 in combination with gemcitabine in Share XCRUK tests drug combo for advanced pancreatic cancerhttps://pharmaphorum.com/news/cruk-tests-drug-combo-for-advanced-pancreatic-cancer/
